ERBB2 and gastric cancer: Medium-sized CTMs, such as CTM3–4, are specific components that could drive chemo-/targeted therapeutic resistance in GC, while those aggregated by ≥ 5 cells are more likely to be involved in HER2-driven liver metastasis.